Ballerup, Denmark
Ballerup, Denmark

Time filter

Source Type

News Article | February 21, 2017
Site: globenewswire.com

·         Net revenues were SEK 74.9 M (13.6 M) ·         EBIT was SEK 4.2 M (-28.1 M) ·         Earnings per share were SEK 0.11 (-1.29) ·         Diluted earnings per share were SEK 0.11 (-1.29) ·         Net revenues were SEK 5.4 M (1.8 M) ·         EBIT was SEK -15.0 M (-5.3 M) ·         Earnings per share were SEK -0.60 (-0.23) ·         Diluted earnings per share were SEK -0.60 (-0.23) ·         Distribution of all Saniona's shares held in Initiator Pharma to Saniona's shareholders decided at an extra ordinary general meeting. ·         Saniona postponed list change to Nasdaq Stockholm following advanced ruling from the listing committee. ·         Research milestone of about SEK 1.5 million obtained from The Michael J. Fox Foundation for Parkinson's Research. ·         Saniona and Upsher Smith extended research collaboration under the drug discovery and development collaboration for neurological diseases, which the parties signed in the beginning of 2016. ·         Saniona filed a clinical trial application in Czech Republic and Hungary for the performance of a Phase 2a study for Tesomet in patients with Prader-Willi Syndrome during the first half of 2017. ·         Saniona's tesofensine partner, Medix, files application for Phase 3 clinical trials in obesity. ·         Saniona reports positive top line results from the Tesomet Phase 2a study in type 2 diabetes. "We have in effect moved the company from a being a discover company to a company with several programs in late stage clinical development in 2016. With the flying start this year, we are setting a pace, which makes me confident for 2017," says Jørgen Drejer, CEO of Saniona. For more information, please contact The information in this interim report is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and Sweden's Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on February 21, 2017. Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,500 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.


News Article | February 21, 2017
Site: globenewswire.com

·         Net revenues were SEK 74.9 M (13.6 M) ·         EBIT was SEK 4.2 M (-28.1 M) ·         Earnings per share were SEK 0.11 (-1.29) ·         Diluted earnings per share were SEK 0.11 (-1.29) ·         Net revenues were SEK 5.4 M (1.8 M) ·         EBIT was SEK -15.0 M (-5.3 M) ·         Earnings per share were SEK -0.60 (-0.23) ·         Diluted earnings per share were SEK -0.60 (-0.23) ·         Distribution of all Saniona's shares held in Initiator Pharma to Saniona's shareholders decided at an extra ordinary general meeting. ·         Saniona postponed list change to Nasdaq Stockholm following advanced ruling from the listing committee. ·         Research milestone of about SEK 1.5 million obtained from The Michael J. Fox Foundation for Parkinson's Research. ·         Saniona and Upsher Smith extended research collaboration under the drug discovery and development collaboration for neurological diseases, which the parties signed in the beginning of 2016. ·         Saniona filed a clinical trial application in Czech Republic and Hungary for the performance of a Phase 2a study for Tesomet in patients with Prader-Willi Syndrome during the first half of 2017. ·         Saniona's tesofensine partner, Medix, files application for Phase 3 clinical trials in obesity. ·         Saniona reports positive top line results from the Tesomet Phase 2a study in type 2 diabetes. "We have in effect moved the company from a being a discover company to a company with several programs in late stage clinical development in 2016. With the flying start this year, we are setting a pace, which makes me confident for 2017," says Jørgen Drejer, CEO of Saniona. For more information, please contact The information in this interim report is information that Saniona (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and Sweden's Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on February 21, 2017. Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Boehringer Ingelheim GmbH, Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona's Boston based spinout Ataxion Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at Nasdaq First North Premier and has about 4,500 shareholders. Pareto Securities is Certified Advisor for Saniona. The company's share is traded under the ticker SANION. Read more at www.saniona.com.


News Article | February 24, 2017
Site: globenewswire.com

Company announcement 24 February 2017 The full version of the Annual Report 2016 for NeuroSearch is available in the enclosed PDF file. In 2016, the NeuroSearch Group (NEUR) posted an operating loss on continuing operations of DKK 6 million (2015: 7 million), which was on a level with the Company's previously announced expectations of an operating loss of DKK 4-6 million. The Company posted a profit of DKK 1 million on discontinued operations (2015: DKK 1 million). NeuroSearch posted an income after tax on continuing operations of DKK 22 million (2015: loss of DKK 7 million). The income for the year includes recycling of currency translation in the amount of DKK 23.5 million. Consolidated profit was an income of DKK 23 million (2015: loss of DKK 6 million). At the end of 2016, cash and cash equivalents totalled DKK 74 million (2015: DKK 78 million). For a complete description of performance in the 2016 financial year, we refer to the Annual Report 2016 of NeuroSearch accompanying this announcement, and which is also available on our website as from today. Outlook for 2017 In 2017, NeuroSearch expects an operating loss in the range of DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any income from the possible sale of Company assets, other potential income from the Company's agreements with Teva, Saniona or others. Karin Garre                                                                       Allan Andersen Chairman                                                                          CEO Contact Allan Andersen, CEO, mobile +45 4016 3864. About NeuroSearch NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S. APPENDIX Financial highlights for the NeuroSearch Group *     The ratios are stated in accordance with "Recommendations and Financial Ratios" issued by The Danish Finance Society. **    Comprehensive income includes unrealised currency translation adjustment and fair value adjustment of the hedge of the net investment in NeuroSearch Sweden AB.


News Article | February 24, 2017
Site: globenewswire.com

Company announcement 24 February 2017 The full version of the Annual Report 2016 for NeuroSearch is available in the enclosed PDF file. In 2016, the NeuroSearch Group (NEUR) posted an operating loss on continuing operations of DKK 6 million (2015: 7 million), which was on a level with the Company's previously announced expectations of an operating loss of DKK 4-6 million. The Company posted a profit of DKK 1 million on discontinued operations (2015: DKK 1 million). NeuroSearch posted an income after tax on continuing operations of DKK 22 million (2015: loss of DKK 7 million). The income for the year includes recycling of currency translation in the amount of DKK 23.5 million. Consolidated profit was an income of DKK 23 million (2015: loss of DKK 6 million). At the end of 2016, cash and cash equivalents totalled DKK 74 million (2015: DKK 78 million). For a complete description of performance in the 2016 financial year, we refer to the Annual Report 2016 of NeuroSearch accompanying this announcement, and which is also available on our website as from today. Outlook for 2017 In 2017, NeuroSearch expects an operating loss in the range of DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any income from the possible sale of Company assets, other potential income from the Company's agreements with Teva, Saniona or others. Karin Garre                                                                       Allan Andersen Chairman                                                                          CEO Contact Allan Andersen, CEO, mobile +45 4016 3864. About NeuroSearch NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S. APPENDIX Financial highlights for the NeuroSearch Group *     The ratios are stated in accordance with "Recommendations and Financial Ratios" issued by The Danish Finance Society. **    Comprehensive income includes unrealised currency translation adjustment and fair value adjustment of the hedge of the net investment in NeuroSearch Sweden AB.


News Article | February 24, 2017
Site: globenewswire.com

Company announcement 24 February 2017 The full version of the Annual Report 2016 for NeuroSearch is available in the enclosed PDF file. In 2016, the NeuroSearch Group (NEUR) posted an operating loss on continuing operations of DKK 6 million (2015: 7 million), which was on a level with the Company's previously announced expectations of an operating loss of DKK 4-6 million. The Company posted a profit of DKK 1 million on discontinued operations (2015: DKK 1 million). NeuroSearch posted an income after tax on continuing operations of DKK 22 million (2015: loss of DKK 7 million). The income for the year includes recycling of currency translation in the amount of DKK 23.5 million. Consolidated profit was an income of DKK 23 million (2015: loss of DKK 6 million). At the end of 2016, cash and cash equivalents totalled DKK 74 million (2015: DKK 78 million). For a complete description of performance in the 2016 financial year, we refer to the Annual Report 2016 of NeuroSearch accompanying this announcement, and which is also available on our website as from today. Outlook for 2017 In 2017, NeuroSearch expects an operating loss in the range of DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any income from the possible sale of Company assets, other potential income from the Company's agreements with Teva, Saniona or others. Karin Garre                                                                       Allan Andersen Chairman                                                                          CEO Contact Allan Andersen, CEO, mobile +45 4016 3864. About NeuroSearch NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S. APPENDIX Financial highlights for the NeuroSearch Group *     The ratios are stated in accordance with "Recommendations and Financial Ratios" issued by The Danish Finance Society. **    Comprehensive income includes unrealised currency translation adjustment and fair value adjustment of the hedge of the net investment in NeuroSearch Sweden AB.


News Article | February 24, 2017
Site: globenewswire.com

Company announcement 24 February 2017 The full version of the Annual Report 2016 for NeuroSearch is available in the enclosed PDF file. In 2016, the NeuroSearch Group (NEUR) posted an operating loss on continuing operations of DKK 6 million (2015: 7 million), which was on a level with the Company's previously announced expectations of an operating loss of DKK 4-6 million. The Company posted a profit of DKK 1 million on discontinued operations (2015: DKK 1 million). NeuroSearch posted an income after tax on continuing operations of DKK 22 million (2015: loss of DKK 7 million). The income for the year includes recycling of currency translation in the amount of DKK 23.5 million. Consolidated profit was an income of DKK 23 million (2015: loss of DKK 6 million). At the end of 2016, cash and cash equivalents totalled DKK 74 million (2015: DKK 78 million). For a complete description of performance in the 2016 financial year, we refer to the Annual Report 2016 of NeuroSearch accompanying this announcement, and which is also available on our website as from today. Outlook for 2017 In 2017, NeuroSearch expects an operating loss in the range of DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any income from the possible sale of Company assets, other potential income from the Company's agreements with Teva, Saniona or others. Karin Garre                                                                       Allan Andersen Chairman                                                                          CEO Contact Allan Andersen, CEO, mobile +45 4016 3864. About NeuroSearch NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S. APPENDIX Financial highlights for the NeuroSearch Group *     The ratios are stated in accordance with "Recommendations and Financial Ratios" issued by The Danish Finance Society. **    Comprehensive income includes unrealised currency translation adjustment and fair value adjustment of the hedge of the net investment in NeuroSearch Sweden AB.


News Article | February 21, 2017
Site: globenewswire.com

Saniona är ett forsknings- och utvecklingsbolag fokuserat på läkemedel för sjukdomar i centrala nervsystemet, autoimmuna sjukdomar, metaboliska sjukdomar och smärtlindring. Bolaget har en omfattande portfölj av potentiella läkemedelskandidater i preklinisk eller klinisk Fas. Forskningen är inriktad på jonkanaler som utgör en unik proteinklass som möjliggör och kontrollerar passage av laddade joner i cellernas membran. Bolaget samarbetar med Boehringer Ingelheim GmbH. Upsher-Smith Laboratories Inc., Productos Medix, S.A de S.V och Sanionas Bostonbaserade spinout Ataxion Inc. Saniona har sitt kontor i Köpenhamn där bolaget har en forskningssite av hög internationell klass. Saniona är noterat på Nasdaq First North Premier och har cirka 4 500 aktieägare. Pareto Securities är Certified Adviser för Saniona. Aktien handlas under tickern SANION. Läs mer på www.saniona.com.


News Article | February 24, 2017
Site: globenewswire.com

NeuroSearch koncernen (NEUR) realiserede i 2016 et underskud fra primær drift af fortsættende aktiviteter på 6 mio.kr. (2015: 7 mio.kr.), hvilket er på niveau med selskabets tidligere offentliggjorte resultatforventninger om et underskud af primær drift på 4-6 mio.kr. Selskabet har haft en mindre indtægt fra de ophørende aktiviteter på i alt 1 mio.kr. (2015: 1 mio.kr.). Årets resultat af fortsættende aktiviteter efter skat blev et overskud på 22 mio.kr. (2015: underskud på 7 mio.kr.). I årets resultat indgår en recirkulering af valutakursregulering positivt med 23,5 mio.kr. Årets resultat for koncernen blev et overskud på 23 mio.kr. (2015: underskud på 6 mio.kr.). Ved udgangen af 2016 bestod kapitalberedskabet af likvider på 74 mio.kr. (2015: 78 mio.kr.). For en komplet beskrivelse af regnskabsåret 2016 henvises til Årsrapport 2016 for NeuroSearch, der ledsager denne meddelelse, og som også kan findes på selskabets hjemmeside fra i dag. Forventninger til 2017 I 2017 forventer NeuroSearch et underskud af primær drift i størrelsesordenen 4,5-5,5 mio.kr. I forventningerne indgår primært omkostninger til fortsat afsøgning af mulighederne for at afdisponere selskabets aktiver, opretholdelse af selskabets børsnotering og opretholdelse af selskabets daglige drift. I forventningerne indgår hverken indtægter fra eventuelt salg af selskabets aktiver eller øvrige mulige indtægter fra selskabets aftaler med Teva, Saniona eller andre.


News Article | February 24, 2017
Site: globenewswire.com

NeuroSearch koncernen (NEUR) realiserede i 2016 et underskud fra primær drift af fortsættende aktiviteter på 6 mio.kr. (2015: 7 mio.kr.), hvilket er på niveau med selskabets tidligere offentliggjorte resultatforventninger om et underskud af primær drift på 4-6 mio.kr. Selskabet har haft en mindre indtægt fra de ophørende aktiviteter på i alt 1 mio.kr. (2015: 1 mio.kr.). Årets resultat af fortsættende aktiviteter efter skat blev et overskud på 22 mio.kr. (2015: underskud på 7 mio.kr.). I årets resultat indgår en recirkulering af valutakursregulering positivt med 23,5 mio.kr. Årets resultat for koncernen blev et overskud på 23 mio.kr. (2015: underskud på 6 mio.kr.). Ved udgangen af 2016 bestod kapitalberedskabet af likvider på 74 mio.kr. (2015: 78 mio.kr.). For en komplet beskrivelse af regnskabsåret 2016 henvises til Årsrapport 2016 for NeuroSearch, der ledsager denne meddelelse, og som også kan findes på selskabets hjemmeside fra i dag. Forventninger til 2017 I 2017 forventer NeuroSearch et underskud af primær drift i størrelsesordenen 4,5-5,5 mio.kr. I forventningerne indgår primært omkostninger til fortsat afsøgning af mulighederne for at afdisponere selskabets aktiver, opretholdelse af selskabets børsnotering og opretholdelse af selskabets daglige drift. I forventningerne indgår hverken indtægter fra eventuelt salg af selskabets aktiver eller øvrige mulige indtægter fra selskabets aftaler med Teva, Saniona eller andre.


News Article | February 24, 2017
Site: globenewswire.com

NeuroSearch koncernen (NEUR) realiserede i 2016 et underskud fra primær drift af fortsættende aktiviteter på 6 mio.kr. (2015: 7 mio.kr.), hvilket er på niveau med selskabets tidligere offentliggjorte resultatforventninger om et underskud af primær drift på 4-6 mio.kr. Selskabet har haft en mindre indtægt fra de ophørende aktiviteter på i alt 1 mio.kr. (2015: 1 mio.kr.). Årets resultat af fortsættende aktiviteter efter skat blev et overskud på 22 mio.kr. (2015: underskud på 7 mio.kr.). I årets resultat indgår en recirkulering af valutakursregulering positivt med 23,5 mio.kr. Årets resultat for koncernen blev et overskud på 23 mio.kr. (2015: underskud på 6 mio.kr.). Ved udgangen af 2016 bestod kapitalberedskabet af likvider på 74 mio.kr. (2015: 78 mio.kr.). For en komplet beskrivelse af regnskabsåret 2016 henvises til Årsrapport 2016 for NeuroSearch, der ledsager denne meddelelse, og som også kan findes på selskabets hjemmeside fra i dag. Forventninger til 2017 I 2017 forventer NeuroSearch et underskud af primær drift i størrelsesordenen 4,5-5,5 mio.kr. I forventningerne indgår primært omkostninger til fortsat afsøgning af mulighederne for at afdisponere selskabets aktiver, opretholdelse af selskabets børsnotering og opretholdelse af selskabets daglige drift. I forventningerne indgår hverken indtægter fra eventuelt salg af selskabets aktiver eller øvrige mulige indtægter fra selskabets aftaler med Teva, Saniona eller andre.

Loading Saniona AB collaborators
Loading Saniona AB collaborators